> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# 4 Observations in Lupin Inspection
- URL: https://www.fdaweb.com/4-observations-in-lupin-inspection/
- Published: 2025-09-16T12:00:00.000Z
- Updated: 2026-09-14T15:21:52.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5159872

FDA has released the form FDA-483 issued following a 7/8-7/17 inspection at the Lupin drug manufacturing facility in Madhya Pradesh, India. The four inspection observations were:

- failure to follow procedures designed to prevent microbiological contamination of drug products purporting to be sterile;
- aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure;
- failure to establish and follow written procedures that describe the examinations to be conducted on appropriate samples of in-process materials of each batch; and
- failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed.